• Relapsing forms of MS (RMS):
  • Clinically isolated syndrome
  • Relapsing-remitting MS (RRMS)
  • Active secondary progressive MS (SPMS)

Dose:300 mg IV → followed 2 weeks later by another 300 mg IV

  • Primary Progressive MS (PPMS)

Dose:600 mg IV every 6 months (starting 6 months after initial dose)

  • 300 mg/10 mL (30 mg/mL) in a single-dose vial
  • Must be diluted before IV infusion
  • Administer by IV infusion only
  • Premedicate 30–60 minutes before infusion with:
    • Methylprednisolone (or equivalent corticosteroid)
    • Antihistamine (e.g., diphenhydramine)
    • Optional antipyretic (e.g., acetaminophen)
  • Infusion duration:
    • Initial doses over 2.5–3.5 hours
    • May reduce time in future if tolerated
  • Mechanism of Action:

    • Humanized monoclonal antibody targeting CD20+ B cells
    • Reduces inflammation and immune-mediated CNS damage in MS
  • Pharmacokinetics:
    • Half-life: ~26 days
    • Cleared via reticuloendothelial system
  • Infusion reactions (rash, fever, hypotension)
  • Respiratory tract infections
  • Skin infections
  • Headache, fatigue
  • Active hepatitis B infection
  • History of life-threatening reaction to Ocrelizumab
  • Avoid live or live-attenuated vaccines
  • Caution with other immunosuppressants (risk of infection ↑)
  • Monitor closely when used with other monoclonal antibodies

                                   Drug Status

Availability
Pregnancy
Breastfeeding
Schedule
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Ocrevus 300mg/10mL Injection 1’s F.Hoffman La-Roche Roche Kenya